| dc.description.abstract | Chemotherapy, one of the most extensively used cancer therapies, usually
damages healthy cells and tissues, resulting in several unwanted side effects,
such as loss of organ function or decreased organ efficiency. One of the most
common used drugs is Doxorubicin (DOX). It is used to treat a variety of
cancers, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma,
and leukemia. Consequently, an injectable hydrogel was designed for non invasive drug delivery, simple drug integration, and locally controlled release at
the target areas. Thiol-ene "click" reaction was used to produce hydrogels from
thiol-functionalized gelatin (GSH) and cross-linker CD-vinyl sulfone (CD-VS). The
physicochemical features of hydrogels containing varying amounts of cross-linker
feed were examined, including gelation time, swelling ratio, porosity, and
degradation rates. To demonstrate the high drug loading capacity and prolonged
drug release of hydrogels, we developed a gelatin-based hydrogel as a drug
delivery vehicle for DOX. Due to the interaction between DOX-CD, the drug
release was observed to depend on CD-VS concentration. In conclusion, we
anticipate that this gelatin-based hydrogel will be a potential option for the
targeted and prolonged administration of hydrophobic medicines to treat cancer. | en_US |
